NCT02501616

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 4, single center, randomized, open-labeled, cross-over design study. The primary objective of the study is to compare effect of dapagliflozine and metformin on endothelial function. Subjects are randomized to initial metformin or initial dapagliflozin group and maintained initial treatment for 8 weeks. During that period, dose of dapagliflozin is maintained 10mg/day and metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' cross-over is followed.

Conditions

• Endothelial Function
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Metformin
DRUG	Dapagliflozin

Timeline

• Start date: 2014-12-01
• Primary completion: 2015-12-01
• First posted: 2015-07-17
• Last updated: 2015-07-17

Locations

1 site across 1 country: South Korea